Overview

Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of SAR442501 in Pediatric Participants With Achondroplasia

Status:
Recruiting
Trial end date:
2027-12-02
Target enrollment:
0
Participant gender:
All
Summary
This is a Phase 2, open-label, multicenter, study to evaluate safety, tolerability and efficacy of SAR442501 in children from birth up to 12 years of age with Achondroplasia.
Phase:
Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Sanofi
Criteria
Inclusion Criteria:

- Participants must have ACH with a confirmed mutation in the FGFR3 gene

- Participants and/or parent(s) or legal representative(s) must be willing and able to
perform all the study procedures to the best of their physical ability.

- Parent(s) or legal representative(s) capable of giving signed informed consent and
participants capable of giving assent when applicable.

Exclusion Criteria:

- Have hypochondroplasia (or the N540K mutation) or short stature condition other than
ACH (eg, trisomy 21, pseudochondroplasia)

- Participants have received any dose of medications or investigational product,
including human growth hormone, IGF-1, intended to affect participants' stature or
body proportions between the completion of OBS16647 and enrollment (Week 0/Day 1/Visit
2).

- Have a history of growth plate closure.

- Long bone fracture within 3 months of enrollment (Week 0/Day 1/Visit 2)

- Current evidence of corneal or retinal disorder/keratopathy.

- Participants have had a previous surgical intervention involving the foramen magnum
(Stage 2 only).

- Hyperphosphatemia.

The above information is not intended to contain all considerations relevant to a potential
participation in a clinical trial.